Hero Laboratories Ltd - Accounts to registrar (filleted) - small 23.1.2
Hero Laboratories Ltd - Accounts to registrar (filleted) - small 23.1.2
| REGISTERED NUMBER: |
| Hero Laboratories Ltd |
| Unaudited Financial Statements |
| for the Year Ended 31st October 2022 |
| Hero Laboratories Ltd (Registered number: 11622921) |
| Contents of the Financial Statements |
| for the Year Ended 31st October 2022 |
| Page |
| Company Information | 1 |
| Statement of Financial Position | 2 |
| Notes to the Financial Statements | 4 |
| Hero Laboratories Ltd |
| Company Information |
| for the Year Ended 31st October 2022 |
| Directors: |
| Registered office: |
| Registered number: |
| Accountants: |
| Accountants |
| 4th Floor |
| 100 Fenchurch Street |
| London |
| EC3M 5JD |
| Hero Laboratories Ltd (Registered number: 11622921) |
| Statement of Financial Position |
| 31st October 2022 |
| 2022 | 2021 |
| Notes | £ | £ | £ | £ |
| Fixed assets |
| Intangible assets | 4 |
| Tangible assets | 5 |
| Investments | 6 |
| Current assets |
| Stocks |
| Debtors | 7 |
| Cash at bank and in hand |
| Creditors |
| Amounts falling due within one year | 8 |
| Net current assets |
| Total assets less current liabilities |
| Creditors |
| Amounts falling due after more than one year |
9 |
| Net assets |
| Capital and reserves |
| Called up share capital | 1,761 | 1,459 |
| Share premium | 3,468,410 | 2,050,710 |
| Retained earnings | (1,553,651 | ) | (869,014 | ) |
| The directors acknowledge their responsibilities for: |
| (a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
| (b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
| Hero Laboratories Ltd (Registered number: 11622921) |
| Statement of Financial Position - continued |
| 31st October 2022 |
| In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered. |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| Hero Laboratories Ltd (Registered number: 11622921) |
| Notes to the Financial Statements |
| for the Year Ended 31st October 2022 |
| 1. | Statutory information |
| Hero Laboratories Ltd is a |
| 2. | Accounting policies |
| Basis of preparing the financial statements |
| Turnover |
| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
| Intangible assets |
| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. |
| An impairment loss has been recognised in the Income Statement, following an assessment at the Statement of Financial Position date indicating the recoverable amount was less than its carrying value. |
| Domains are being amortised evenly over their estimated useful life. |
| Patents and licences are being amortised evenly over their estimated useful life. |
| Intellectual Property are being amortised evenly over their estimated useful life. |
| Capital restructuring costs has been impaired fully, as in the opinion of the directors, this is not recoverable. |
| Tangible fixed assets |
| Fixtures and fittings | - |
| Computer equipment | - |
| Investments in subsidiaries |
| Investments in subsidiary undertakings are recognised at cost. |
| Stocks |
| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date. |
| Hero Laboratories Ltd (Registered number: 11622921) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31st October 2022 |
| 2. | Accounting policies - continued |
| Deferred tax |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| Pension costs and other post-retirement benefits |
| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
| 3. | Employees and directors |
| The average number of employees during the year was |
| 4. | Intangible fixed assets |
| Patents | Capital |
| and | Intellectual | restructuring |
| Domains | licences | property | costs | Totals |
| £ | £ | £ | £ | £ |
| Cost |
| At 1st November 2021 |
| Additions |
| At 31st October 2022 |
| Amortisation |
| At 1st November 2021 |
| Amortisation for year |
| At 31st October 2022 |
| Net book value |
| At 31st October 2022 |
| At 31st October 2021 |
| Hero Laboratories Ltd (Registered number: 11622921) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31st October 2022 |
| 5. | Tangible fixed assets |
| Fixtures |
| and | Computer |
| fittings | equipment | Totals |
| £ | £ | £ |
| Cost |
| At 1st November 2021 |
| Additions |
| At 31st October 2022 |
| Depreciation |
| At 1st November 2021 |
| Charge for year |
| At 31st October 2022 |
| Net book value |
| At 31st October 2022 |
| At 31st October 2021 |
| 6. | Fixed asset investments |
| Shares in |
| group |
| undertakings |
| £ |
| Cost |
| At 1st November 2021 |
| and 31st October 2022 |
| Net book value |
| At 31st October 2022 |
| At 31st October 2021 |
| 7. | Debtors: amounts falling due within one year |
| 2022 | 2021 |
| £ | £ |
| Trade debtors |
| Amounts owed by group undertakings |
| Other debtors |
| 8. | Creditors: amounts falling due within one year |
| 2022 | 2021 |
| £ | £ |
| Bank loans and overdrafts |
| Trade creditors |
| Taxation and social security |
| Other creditors |
| Hero Laboratories Ltd (Registered number: 11622921) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31st October 2022 |
| 9. | Creditors: amounts falling due after more than one year |
| 2022 | 2021 |
| £ | £ |
| Bank loans |
| 10. | Related party disclosures |
| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group. |